Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Karyopharm Therapeutics Inc.

www.karyopharm.com

Latest From Karyopharm Therapeutics Inc.

Deals Shaping The Medical Industry, November 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2017.

Deals BioPharmaceutical

Ono Bulks Up MAb R&D With Second Swiss Biotech Deal

Human-derived monoclonal antibodies targeted against neurodegenerative diseases is the subject of a deal between Japan's Ono Pharmaceutical and Zurich-based biotech Neurimmune.

Deals Neurology

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

Big Guns Ready To Roll Into Madrid: ESMO Preview

The stage is set for AstraZeneca to shine and showcase the benefits of its immunotherapy Imfinzi in lung cancer as pharmaceutical companies large and small head to Europe's largest oncology meeting.

ImmunoOncology Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Inflammation
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karyopharm Therapeutics Inc.
  • Senior Management
  • Michael Kauffman, MD, PhD, CEO
    Sharon Shacham, PhD, Pres. & CSO
    Mike Todisco, VP, Fin.
    Christopher Primiano, VP, Operations & Bus. Dev.
  • Contact Info
  • Karyopharm Therapeutics Inc.
    Phone: (617) 658-0600
    85 Wells Ave.
    2nd Fl.
    Newton, MA 02459
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register